ArticleEnvironment & health (Washington, D.C.)2026
Metabolomics-Driven Discovery of Targets for Hepatocytotoxicity Induced by Triphenyltin Chloride through Mitochondrial Function Involving HSD17B10 and HADH.
Article in Environment & health (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triphenyltin chloride (TPTC), a member of the organotin family, has been widely restricted due to its endocrine-disrupting effects. Nevertheless, TPTC continues to be detected in aquatic environments and poses potential health risks owing to its persistence and bioaccumulation. Although previous studies have shown that triphenyltin compounds can disrupt lipid homeostasis through nuclear receptor pathways involving retinoid X receptor (RXR) and peroxisome proliferator-activated receptors (PPARs), whether TPTC exerts hepatocytotoxicity through direct metabolic targets remains unclear. This study employed a metabolomics-driven target discovery strategy to analyze intracellular metabolite extracts from HepG2 cells exposed to TPTC for 24 h, aiming to investigate the underlying molecular mechanisms of TPTC-induced metabolic toxicity. Untargeted global metabolomics analysis revealed that TPTC exposure caused significant disturbances in hepatic lipid metabolism, characterized by the accumulation of medium- and long-chain fatty acids and depletion of key metabolites associated with fatty acid β-oxidation. Pathway enrichment analysis and protein-protein interaction network analysis further indicated that two mitochondrial dehydrogenases involved in fatty acid catabolismhydroxysteroid 17β-dehydrogenase 10 (HSD17B10) and hydroxyacyl-CoA dehydrogenase (HADH)are potential metabolic targets responsible for the observed alterations. Molecular docking, surface plasmon resonance, and cellular thermal shift assays confirmed direct interactions between TPTC and both HSD17B10 and HADH, with binding affinities at the micromolar level. Functional validation demonstrated that TPTC disrupts mitochondrial respiratory function and redox balance by interfering with HADH- and HSD17B10-dependent generation of acetyl-CoA and NADH, leading to mitochondrial dysfunction and oxidative stress. In summary, this study reveals a previously underappreciated mechanism of TPTC toxicity involving mitochondrial metabolism, extending the current understanding of its toxicological pathways beyond nuclear receptor-mediated signaling to include direct disruption of mitochondrial energy and redox metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.